Variations in statin prescribing for primary cardiovascular disease prevention: Cross-sectional analysis

BMC Health Services Research

Volumn 14, Issue 1, 2014, Pages

  Fleetcroft, Robert ^a   Schofield, Peter ^b   Ashworth, Mark ^b  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cardiovascular diseases; Hydroxymethylglutaryl CoA reductase inhibitors; Primary health care

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; CARDIOVASCULAR DISEASES; CLINICAL PRACTICE; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; PRIMARY HEALTH CARE; PRIMARY PREVENTION; STATISTICS AND NUMERICAL DATA; UNITED KINGDOM;

ADULT; AGED; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; ENGLAND; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PRACTICE PATTERNS, PHYSICIANS'; PRIMARY HEALTH CARE; PRIMARY PREVENTION;

EID: 84908394222     PISSN: None     EISSN: 14726963     Source Type: Journal    
DOI: 10.1186/1472-6963-14-414     Document Type: Article

References (34)

1. World Health Organisation: The 10 leading causes of death by broad income group (2008). In Fact sheet No 310. Geneva: 2012.
2. Cholesterol Treatment Trialists' (CTT) Collaborators: The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380(9841):581-590.
3. Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N: A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007, 11(14):1-160. iii-iv.
4. Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn L, Greenlund K, Daniels S, Nichol G, Tomaselli GF, Arnett DK, Fonarow GC, Ho PM, Lauer MS, Masoudi FA, Robertson RM, Roger V, Schwamm LH, Sorlie P, Yancy CW, Rosamond WD: Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association's strategic Impact Goal through 2020 and beyond. Circulation 2010, 121(4):586-613.
5. National Institute for Health and Care Excellence: CG67 Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease: full guideline. London: 2008.
6. World Health Organisation: Prevention of Cardiovascular Disease (CVDs). In Geneva: World Health Organisation; 2007. Available: http://www.who.int/cardiovascular-diseases/guidelines/Pocket-GL-information/en/ [accessed 18/09/2014]
7. Stone NJ, Robinson J, Lichtenstein A: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. In Circulation. Dallas: American Heart Association; 2013.
8. National Clinical Guideline Centre: Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease [online]. In 2014. London, National Institute for Health and Care Excellence. Available: http://www.nice.org.uk/guidance?action=download&o=66547 [accessed 18/09/2014].
9. The NHS Confederation: The new GMS contract [online]. 2003. London, The British Medical Association and the NHS Confederation. Available; http://webarchive.nationalarchives.gov.uk/+/www.dh.gov.uk/en/Healthcare/Primarycare/Primarycarecontracting/GMS/DH-4125637 [accessed 18/09/2014]
10. Department of Health: Free NHS Health Check [online]. In 2013. London, Department of Health. Available: http://www.healthcheck.nhs.uk/ [accessed 18/09/2014]
11. Millett C, Gray J, Wall M, Majeed A: Ethnic disparities in coronary heart disease management and pay for performance in the UK. J Gen Intern Med 2009, 24(1):8-13.
12. Ward PNP, Leger A: How equitable are GP practice prescribing rates for statins?: an ecological study in four primary care trusts in North West England. Int J Equity Health 2007, 6:2.
13. Packham C, Robinson J, Morris J, Richards C, Marks P, Gray D: Statin prescribing in Nottingham general practices: a cross-sectional study. J Public Health Med 1999, 21(1):60-64.
14. Thomsen RW, Johnsen SP, Olesen AV, Mortensen JT, Boggild H, Olsen J, Sorensen HT: Socioeconomic gradient in use of statins among Danish patients: population-based cross-sectional study. Br J Clin Pharmacol 2005, 60(5):534-542.
15. Ashworth M, Lloyd D, Smith RS, Wagner A, Rowlands G: Social deprivation and statin prescribing: a cross-sectional analysis using data from the new UK general practitioner 'Quality and Outcomes Framework'. J Public Health 2007, 29(1):40-47.
16. Majeed A, Moser K, Maxwell R: Age, sex and practice variations in the use of statins in general practice in England and Wales. J Public Health Med 2000, 22(3):275-279.
17. Mantel-Teeuwisse AK, Verschuren WM, Klungel OH, Kromhout D, Lindemans AD, Avorn J, Porsius AJ, de Boer A: Undertreatment of hypercholesterolaemia: a population-based study. Br J Clin Pharmacol 2003, 55(4):389-397.
18. Tonstad S, Rosvold EO, Furu K, Skurtveit S: Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001. J Intern Med 2004, 255(4):494-502.
19. Sheppard JP, Singh S, Fletcher K, McManus RJ, Mant J: Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK: cross sectional study. BMJ 2012, 345:e4535.
20. Neutel CI, Morrison H, Campbell NR, de Groh M: Statin use in Canadians: trends, determinants and persistence. Can J Public Health 2007, 98(5):412-416.
21. Stocks N, Ryan P, Allan J, Williams S, Willson K: Gender, socioeconomic status, need or access? Differences in statin prescribing across urban, rural and remote Australia. Aust J Rural Health 2009, 17(2):92-96.
22. Wu J, Zhu S, Yao GL, Mohammed MA, Marshall T: Patient factors influencing the prescribing of lipid lowering drugs for primary prevention of cardiovascular disease in UK General Practice: a National Retrospective Cohort Study. PLoS One 2013, 8(7):e67611.
23. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyorala K, Reiner Z, Keil U, Group ES: EUROASPIRE III: Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil 2010, 17(5):530-540.
24. Department of Health: The NHS Outcomes Framework 2013/14 [online]. 2012, London, Department of Health. Available: https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/213055/121109-NHS-Outcomes-Framework-2013-14.pdf [accessed 18/09/2014]
25. Katz D, Ali A: Preventive Medicine, Integrative Medicine & the Health of the Public [online]. In Washington, DC: Institute of Medicine; 2009. Available http://www.iom.edu/~/media/Files/Activity%20Files/Quality/IntegrativeMed/Preventive%20Medicine%20Integrative%20Medicine%20and%20the%20Health%20of%20the%20Public.pdf [accessed 18/09/2014].
26. World Health Organisation: International language for drug utilization research [online]. In Norway: WHO Collaborating Centre for Drug Statistics Methodology; 2012. Available: http://www.whocc.no/ [accessed 18/09/2014]
27. National Primary Care Research and Development Centre: General Medical Services Database. In Manchester: University of Manchester; 2008.
28. Mclennan D, Barnes H, Noble M, Davies J, Garrett E, Dibben C: The English Indices of Deprivation 2010. Crown 2011,
29. Health and Social Care Information Centre: Quality and Outcomes Framework 2006-7 [online]. In Leeds: Department of Health; 2007. Available: http://www.hscic.gov.uk/catalogue/PUB05997 [accessed 18/09/2014]
30. Fischer MA, Stedman MR, Lii J, Vogeli C, Shrank WH, Brookhart MA, Weissman JS: Primary medication non-adherence: analysis of 195,930 electronic prescriptions. J Gen Intern Med 2010, 25(4):284-290.
31. Fleetcroft R, Parekh-Bhurke S, Howe A, Cookson R, Swift L, Steel N: The UK pay-for-performance programme in primary care: estimation of population mortality reduction. Br J Gen Pract 2010, 60(578):e345-e352.
32. Shepherd J, Barter P, Carmena R, Deedwania P, Fruchart JC, Haffner S, Hsia J, Breazna A, LaRosa J, Grundy S, Waters D: Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006, 29(6):1220-1226.
33. Townsend NWK, Bhatnagar P, Smolina K, Nichols M, Leal J, Luengo-Fernandez R, Rayner M: Coronary heart disease statistics 2012 edition. In London: British Heart Foundation; 2012.
34. Sheppard JP, Fletcher K, McManus RJ, Mant J: Missed opportunities in prevention of cardiovascular disease in primary care: a cross-sectional study. Br J Gen Pract 2014, 64(618):e38-e46.